Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Medical Physics, 7(50), p. 4600-4612, 2023

DOI: 10.1002/mp.16346

Links

Tools

Export citation

Search in Google Scholar

A novel tool for predicting the dose distribution of non‐sealed <sup>188</sup>Re (Rhenium) resin in non‐melanoma skin cancers (NMSC) patients

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractBackgroundHigh‐dose rate brachytherapy using a non‐sealed 188Rhenium resin (188Re) is a recently approved treatment option for non‐melanoma skin cancer (NMSC). The treatment goal is to deliver a personalized absorbed dose to the deepest point of neoplastic infiltration corresponding to the minimal target dose. The treatment consists of the application of a 188Re‐based resin over a plastic foil placed on the target skin surface. However, there is no treatment planning tool to assess the 188Re activity needed for a personalized treatment.PurposeThe paper aims to present a novel Monte Carlo (MC)‐based tool for 188Re‐based resin activity and dose calculation, experimentally validated using Gafchromic EBT3 films.MethodsMC simulations were carried out using FLUKA modeling density and composition of 188Re resin. The MC‐based look up table (LUT) was incorporated in an ad hoc developed tool. The proposed tool allows the personalized calculation of treatment parameters (i.e., activity to be dispensed, the treatment duration, and dose volume histograms), according to the target dimension. The proposed tool was compared using Bland–Altman analysis to the previous calculation approaches conducted using VARSKIN in a retrospective cohort of 76 patients. The tool was validated in ad hoc experimental set ups using a stack of calibrated Gafchromic EBT3 films covered by a plastic film and exposed using a homogenous activity distribution of 188Re eluate and a heterogeneous activity distribution of 188Re resin mimic the patient treatment.ResultsThe agreement between the proposed tool and VARSKIN was evaluated on the investigated cohort with median range of target area, target depth, and treatment time equal to 4.8 [1.0–60.1] cm2, 1.1 [0.2–3.0] mm, and 70 [21–285] min, with a median range of target dose (Gy) of 23.5 [10–54.9]. The calculated minimal target doses, ranged from 1% to 10% for intermediate target depths (1.2 ± 0.7 mm), while showing significant differences in the estimation of superficial (maximal) target doses. The agreement between MC calculation and measurements at different plans in a stack of Gafchromic EBT3 films was within 10% for both the homogenous and heterogeneous activity distribution of 188Re. Worst agreements were observed for absorbed doses lower than 0.3 Gy.ConclusionsOur results support the implementation of our MC‐based tool in the practical routine for calculating the 188Re resin activity and treatment parameters necessary for obtaining the prescribed minimal target dose.